Publications by authors named "Chiara di Giovanni Bezzi"
Article Synopsis
- Scientists studied older patients with a type of leukemia called acute myeloid leukemia (AML) to find out what factors affect their survival chances.
- They found that early response to treatment and specific health risks can help predict which patients will do better.
- They also discovered that having other health problems, like lung disease or low albumin levels, can make patients weaker and more likely to face complications, influencing how long they might live.
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
Eur J Haematol
June 2022
Venetoclax (VEN) and hypomethylating agent (HMAs) regimens are emerging as the standard of care for unfit for chemotherapy acute myeloid leukemia (AML) patients, but the safety and feasibility of a total outpatient management have not been fully investigated. Fifty-nine AML patients with active disease received VEN and HMAs. Nineteen out of 59 (32.
View Article and Find Full Text PDFCarfilzomib-lenalidomide-dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis of 197 RRMM patients (pts) between January 2016 and March 2018 in six Italian hematologic centers, with the aim to evaluate efficacy and safety of KRd in real-life. At KRd initiation 27% carried high risk cytogenetic abnormalities (HRCA) [del17p and/or t(4;14) and/or t(14;16)], median number of prior lines of therapy was 2 (1-8), nearly all pts (96%) received prior bortezomib (18% refractory) while 45% were exposed to lenalidomide (R; 22% refractory).
View Article and Find Full Text PDF